IMRT 2018

PACIFIC study design

PACIFIC: NSCLC

Phase 3, randomised, double-blind, placebo-controlled, multicentre study

Durvalumab i.v. 10 mg/kg q2w up to 12 months (n=468)

• Locally advanced, unresectable (Stage III) NSCLC (squamous and non-squamous) • Absence of progression following at least two cycles of platinum-based chemotherapy concomitant with radiation therapy

2 : 1

Placebo i.v. q2w (n=234)

Closed to accrual March 2016 PFS: Q2 2017 OS: Q2 2018

Co-primary endpoints – PFS and OS • RECIST v1.1 assessment at screening and q8w thereafter

ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct2/show/NCT02125461 Antonia S, et al. Poster presented at ESMO Symposium on Immuno-oncology 2014. Poster 16TiP

See slide notes for additional study details

Durvalumab is an investigational drug and is not approved for use in any country